<DOC>
	<DOCNO>NCT01741727</DOCNO>
	<brief_summary>A study ABT-414 subject solid tumor .</brief_summary>
	<brief_title>A Study ABT-414 Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<criteria>1 . Subjects must solid tumor type likely overexpress Epidermal Growth Factor Receptor ( EGFR ) ( Phase 1 ) 2 . Subjects Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 3 . Subjects available tumor tissue 4 . Subjects adequate bone marrow , renal , hepatic function follow : Bone marrow : Absolute neutrophil count ( ANC ) &gt; /= 1,500/mm3 Platelets &gt; /= 100,000/mm3 ; Hemoglobin &gt; /= 9.0 g/dL Renal function : Serum creatinine &lt; /= 1.5 time upper limit institution 's normal range Hepatic function : Bilirubin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &lt; /= 1.5 time upper limit institution 's normal range . Subjects liver metastasis may AST ALT &lt; /= 5.0 x upper limit normal . 5 . Subjects Phase 2 portion must squamous cell NonSmall Cell Lung Cancer ( NSCLC ) 6 . Eligibility restrict subject confirm EGFR amplification EGFR amplify cohort 1 . The subject uncontrolled metastases central nervous system ( CNS ) . Subjects brain metastasis eligible provide show clinical radiographic stable disease least 28 day definitive therapy receive prior whole brain radiation ( Phase 1 ) . 2 . The subject receive anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal , biologic , investigational therapy within period 28 day prior first dose ABT414 . 3 . The subject unresolved clinically significant toxicity prior anticancer therapy , define Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 high . 4 . The subject major surgery within 28 day prior first dose ABT414 . 5 . The subject history immunologic reaction Immunoglobulin G ( IgG ) contain agent . 6 . Phase 2 portion : The subject previous concurrent cancer distinct primary site histology NSCLC , except cervical carcinoma situ , nonmelanoma carcinoma skin situ carcinoma bladder . Any cancer curatively treat great 3 year prior entry permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>